Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

oing-christoph
Function
YOC and RTF member
Country

United Kingdom

Address
Sir Bobby Robson Clinical Trials Research Unit
Department of Cancer Services
Freeman Hospital
Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Road
NE7 7DN

What is your current activity?

Currently, I am working as a clinical academic and NUPAcT fellow at Newcastle University CRUK Drug Discovery Unit and as honorary consultant medical oncologist at the early phase trials unit located at the Northern Centre of Cancer Care at the Freeman Hospital in Newcastle upon Tyne. Alongside, I am a research fellow and clinical advisor at Astex Pharmaceuticals, a drug discovery biotech company based in Cambridge, UK. This is a novel three-split position between the three above mentioned institutions as part of a Newcastle University Academic Track together with Astex as an external partner providing a comprehensive learning environment spanning the continuum from pre-clinical research for drug target identification, design of new targeting agents and their clinical application as part of early phase clinical trials.

Apart from this, I am chairing the young oncologists working group of the German Society of Hematology and Oncology (DGHO) and within ESMO I am active member of the ESMO Young Oncologist Committee and the Resilience Task Force with a special interest in modern education and improvement of young oncology professionals’ work environment to prevent burnout.

What motivates you?

Tackling cancer from both angles, clinical care and (pre-)clinical research is very inspiring and rewarding. Asking questions from a clinical point of view and and translating them into research projects with direct impact on patient care is what makes being a clinical academic my area of interest. The complexity of cancer patient care, the ever growing multimodal armamentarium to treat cancer and the various patients’ needs demand interdisciplinary cooperation and thus I very much enjoy being part of inspiring teams of clinicians and researchers at a time. Beyond this, helping to assess and address the needs of young professionals in the field of medical oncology within dedicated teams of societies such as ESMO is also a huge motivation. Making a difference in future cancer care together is one of my personal career goals.

Why did you choose to become a medical oncologist?

Cancer in general is a life threatening and unfortunately clever disease and as such extremely interesting to study and work on. Medical Oncology is a rapidly evolving field with an incredible pace in the development of novel treatment options based on basic, translational and clinical research results, which are rapidly being implemented into patient care. The close interaction between research and clinics in medical oncology and the high interdisciplinarity in clinics and between academic and industrial institutions fascinates me and the option to do both as a clinical academic within dedicated teams of interdisciplinary specialists made me pursue a career in medical oncology.

What does your involvement with ESMO and the Young Oncologists Committee (YOC) mean to you?

ESMO has given me invaluable support and helped me to develop my career through providing a network of enthusiastic young oncologists within the YOC and more senior experts. ESMO has shown me that networking is key to successful personal career development. Being part of the YOC is very inspiring and I am really grateful for this experience, which also led me to establish a YO working group within the German Society of Hematology and Oncology.

Moreover, ESMO was awarding me a translational research fellowship at The Manchester Cancer Research Center and Christie NHS Foundation Trust, nominated me as YOC representative for the EMUC scientific committee, invited me to contribute to the summer schools for med students, lately allowed me to participate in the 2022 class of the leaders generation programme (LGP), and to become a member of the Resilience Task Force to help improve the work environment for oncologists across the globe.

Nothing left to say but THANK YOU ESMO as all this just came to me since I became a YOC member and got involved in various ESMO activities.

Do you have some good advice you would like to share with your international colleagues?

ESMO is truly dedicated to improve cancer care virtually everywhere and ESMO appreciates that today’s YOs are the future work force of medical oncology. ESMO provides a networking platform for YOs and ESMO is really keen to support YOs wherever they are with various educational events and resources, including ESMO Oncology PRO and the YO4YO sessions. So my advice really is to familiarise yourself with all the great opportunities ESMO provides for networking, education and personal development, including the YO tracks at the ESMO conferences, the preceptorships and other courses, and so much more. Get in touch and get involved!

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.